| Literature DB >> 24451753 |
Daniel Y C Heng1, Toni K Choueiri1.
Abstract
The treatment paradigm in metastatic renal cell carcinoma (mRCC) has evolved over the last 5 years. There are now seven approved targeted therapies against the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. The use of targeted therapy, sequences, combinations, and investigational compounds will be discussed. Prognostic and predictive tools are detailed, although much work must be done to find predictive biomarkers in an effort to individualize therapy for patients.Entities:
Year: 2012 PMID： 24451753 DOI： 10.14694/EdBook_AM.2012.32.25
Source DB: PubMed Journal: Am Soc Clin Oncol Educ Book ISSN： 1548-8748